Furthermore, therapeutic targeting of RICTOR and MYC amplifications, which were significantly enriched in tumors with PD‐L1 CPS ≥5, previously demonstrated synergistic effects in several cancer types other than GC.28, 29, 30, 31. This evidence concerns the gene MYC and gastric cancer.